COSCIENS Biopharma Inc.
COSCIENS Biopharma Inc. (CSCI) Revenue
Annual & quarterly revenue history · segment & region breakdown
CSCI · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsCOSCIENS Biopharma Inc. trailing twelve-month (TTM) revenue is $0.01B, an increase of 92.96% year-over-year from $0.01B in FY2024.
Revenue trend
2024 – 2005 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2024-12-31 | $0.01B | +$0.01B | +92.96% |
| 2023-12-31 | $0.01B | -$0.01B | -50.98% |
| 2022-12-31 | $0.01B | +$0.00B | +8.05% |
| 2021-12-31 | $0.01B | +$0.00B | +13.73% |
| 2020-12-31 | $0.01B | +$0.00B | +20.27% |
| 2019-12-31 | $0.01B | +$0.00B | +15.85% |
| 2018-12-31 | $0.01B | -$0.00B | -17.20% |
| 2017-12-31 | $0.01B | +$0.00B | +1.04% |
| 2016-12-31 | $0.01B | +$0.00B | +32.34% |
| 2015-12-31 | $0.01B | +$0.00B | +0.38% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income COSCIENS Biopharma Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
COSCIENS Biopharma Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from COSCIENS Biopharma Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CSCI revenue · 4 questionsCSCI's trailing twelve-month (TTM) revenue is $0.01B. That is an increase of 92.96% year-over-year from $0.01B in FY2024.
▸ Source: FMP · COSCIENS Biopharma Inc. SEC filings · GAAP · COSCIENS Biopharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026